Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hydralazine/magnesium valproate off-label use

Hydralazine/magnesium valproate off-label use Reactions 1680, p159 - 2 Dec 2017 Hydralazine/magnesium valproate off- label use Skin rash: case report In a study, a patient [age and sex not stated] was described, who developed a skin rash following the off-label use of hydralazine and magnesium valproate [Transkrip; routes and time to reaction onset not stated; not all dosages stated]. The patient was diagnosed with myelodysplastic syndrome (MDS). The patient was started on combination therapy with daily dose hydralazine slow release formulation tablets and magnesium valproate slow release tablets 700mg, 30mg/kg three times daily for myelodysplastic syndrome; both drugs were administered 5 days a week. However, the patient developed a skin rash. The skin rash disappeared without any corrective treatment. Author comment: "The aim of this study is to evaluate the clinical efficacy and safety of hydralazine, [magnesium valproate] in a case series of MDS patients treated in a compassionate manner." "All patients were informed that the administration of this drug combination was off-label". "Most toxicity was transient, grade 1–2, and did not require dose reduction or interruption of treatment." "[O]nly one patient developed a skin rash that disappeared without treatment." Candelaria M, et al. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIPTM) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Hydralazine/magnesium valproate off-label use

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Download PDF
1 page

Hydralazine/magnesium valproate off-label use

Abstract

Reactions 1680, p159 - 2 Dec 2017 Hydralazine/magnesium valproate off- label use Skin rash: case report In a study, a patient [age and sex not stated] was described, who developed a skin rash following the off-label use of hydralazine and magnesium valproate [Transkrip; routes and time to reaction onset not stated; not all dosages stated]. The patient was diagnosed with myelodysplastic syndrome (MDS). The patient was started on combination therapy with daily dose hydralazine slow release...
Loading next page...
 
/lp/springer-journals/hydralazine-magnesium-valproate-off-label-use-8NKYQJpGPe

References (1)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-39090-2
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p159 - 2 Dec 2017 Hydralazine/magnesium valproate off- label use Skin rash: case report In a study, a patient [age and sex not stated] was described, who developed a skin rash following the off-label use of hydralazine and magnesium valproate [Transkrip; routes and time to reaction onset not stated; not all dosages stated]. The patient was diagnosed with myelodysplastic syndrome (MDS). The patient was started on combination therapy with daily dose hydralazine slow release formulation tablets and magnesium valproate slow release tablets 700mg, 30mg/kg three times daily for myelodysplastic syndrome; both drugs were administered 5 days a week. However, the patient developed a skin rash. The skin rash disappeared without any corrective treatment. Author comment: "The aim of this study is to evaluate the clinical efficacy and safety of hydralazine, [magnesium valproate] in a case series of MDS patients treated in a compassionate manner." "All patients were informed that the administration of this drug combination was off-label". "Most toxicity was transient, grade 1–2, and did not require dose reduction or interruption of treatment." "[O]nly one patient developed a skin rash that disappeared without treatment." Candelaria M, et al. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIPTM)

Journal

Reactions Weekly – Springer Journals

Published: Dec 2, 2017

There are no references for this article.